Biochips for express analysis of

metabolic imbalance in human’s

body

R&D Bioplasmonics

Objectives

Problem

350 million diabetes patients in the world

Urgent necessity: Reliable prediction of diseases

and risk of unfavorable outcome of disease

Solution

Biochips: Quantitative information

glycated hemoglobin level

glycated albumin level

Market

Market

Point-of-care HbA1c testing segment.

Ion Exchange Chromatography

(Bio-Rad, Drew et al.)

High-Performance Liquid

Chromatography (HPLC)

Boronate Affinity Chromatography

(EKFdiagnostics/Que-Test)

Immunoassay Method (Bayer,

Beckman, Coulter, Olympus,

Roche, Diazyme/GlycoGap et al.)

* Capillarys-2 Flex Piercing, Sebia

Quo-Test

SERS Biochips

Raman spectroscopy

Nanoplasmonics

Biotechnology

Surface-Enhanced

Raman Scattering (SERS)

Raman spectroscopy = fingerprint of molecules

Additional signal

enhancement over 107

SERS Biochips

PDDA Au nanoparticles

HbA1c

Phenylboronic acid Regular

dielectric films

Facet dielectric films

Metallic clusters High-sensitive biochip

Advantages

High sensitivity (SERS signal >107) => Low concentration

detection (1-2 ng/ml)!

Noninvasive analyze

No sample preparation and simple exploitation

Flexibility

Cheap price

Product Enhancement Background

signal

Price

Project SERS substrates 107 low 10$

Ranishaw Diagnostics (UK)/ Klarite 104-106 high $500 for 5

Silmeco/SERStrate 104 low $315 for 5

Diagnostic anSERS Inc./P-SERS 105 low $45 for 6

Applications

Cell Culture (DMEM)

Diagnostics of diabetes, renal

disease,hypothyroidism

Identification of cancer markers

(in future): oncology

Glycated hemoglobin and albumin

After cancer

cell cultivation Before cancer

cell cultivation

Team

Andrey Sarychev

CEO, PhD, Dr. Sci., Professor

Supervision, design and implementation of biochips

Experience of research in material science, plasmonics,

antenna design, optical chemical and biosensors

Andrey Ivanov R&D, PhD

Design and optimization of biochips

Experience of science research in plasmonics

Tatyana Karmakova Сlinician, PhD, Dr. Sci.

Clinical research and testing

Experience of cancer processes research

Maria Shcherbak Manager, PhD

Customer relations. Fundraising

Experience of successful startups (LumInnoTech LLC,

HandyPower LLC).

Project development plan

Stage 1

Development of

industrial designs

Stage 2

Biochips development,

testing

Stage 3

Sale of licenses (Ranishaw,

Silmeco, Diagnostics an

SERS Inc.)/

Manufacturing of biochips,

software, sales

Requirement:

— Investment – 20 million rubles

— Partner – producer of diagnostics spectral devices

1 year 2 year 3 year 4 year 5 year 6 year

Proceeds (biochips

without test systems),

thousands of rubles

0 0 7 189 55 494 67 107 68 523